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Toxic epidermal necrolysis (TEN) is a drug-related fatal disease. Extensive necrosis of the
epidermis can lead to serious complications. This report describes two cases of TEN,
associated with deﬂazacort (DFZ), in two boys, aged 4 years and 14 years, with
nephrotic syndrome (NS). The 14-year-old male teenager received DFZ following NS
relapse. After 17 days, pruritic papules appeared on the lower extremities. Another case
involved a 4-year-old boy receiving DFZ and enalapril. After a 41-day DFZ treatment
period, erythematous papules appeared on the palms and soles. Within 3 days, both
boys developed widespread skin lesions (450%) and were admitted to the intensive
care unit for resuscitative and supportive treatment. The patients showed improvement
after intravenous immunoglobulin-G therapy. Owing to the rapid, fatal course of TEN,
clinicians need to be aware of the adverse effects of this drug when treating cases of NS.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Toxic epidermal necrolysis (TEN) is typically a drug-related
fatal disease characterized by necrosis and destruction of the
entire epidermal skin layer [1]. Nephrotic syndrome (NS) is
treated with steroids such as prednisolone (PD). However,
because of the adverse effects, such as osteoporosis, growth
retardation, and weight gain, associated with PD treatment,
other drugs with fewer side effects, such as deﬂazacort (DFZ;
an oxazoline derivative), have been recommended [2]. Among
the 94 patients with NS who received steroid therapy in
Sanggye Paik Hospital, Seoul, Korea between 2001 and 2012,
three patients who received DFZ developed TEN. We have
reported one of these cases previously [3]; herein, we describe
the two other cases of TEN related to DFZ in two boys aged
4 years and 14 years.n Society of Nephrology. Publi
c-nd/4.0/).
rics, Sanggye Paik Hospi-
ngil-ro 1342, Nowon-gu,Case report
Case 1
A 14-year-old boy, who was diagnosed with NS at 8 years of
age, received PD as the initial treatment. After 4 months of PD
treatment, remission was achieved. However, because of NS
relapse, the treatment was switched to DFZ for 14 days; DFZ
treatment was then tapered. He was also receiving risperidone
(0.5 mg, BID) and atomoxetine (25 mg QD) since 8 years of age for
the treatment of mental retardation. After 6 years, he again
received DFZ (24 mg TID) daily owing to proteinuria. After a 17-
day treatment period, pruritic papules and patches appeared on
the lower extremities. He was admitted 19 days after medication
was initiated, after the skin lesions indicated an extensive spread
within 3 days. Laboratory tests revealed awhite blood cell count of
7,040 cells/mm3, C-reactive protein level of 0.3 mg/dL, and
negative results for human immunodeﬁciency virus and Myco-
plasma pneumonia antigen. On hospital Day 2, the skin could be
easily peeled off, similar to that noted in burn injuries (Fig. 1).
Hence, he was transferred to the intensive care unit for infection
prevention and conservative care. All medications wereshed by Elsevier. This is an open access article under the CC BY-NC-ND
Figure 1. Typical pattern of toxic epidermal necrolysis: erythema,
blistering, and full-thickness epidermal loss is seen over the
entire body.
Figure 2. Erosions and crusts on the lips and multiple bullae on the
face and chest.
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total, 4.51 g/kg) was administered according to the severity of the
skin lesions. After 18 days of treatment, the skin lesions improved.
The patient needed conservative management, and was dis-
charged on hospital Day 25. After discharge, the NS has been
controlled by switching the treatment to PD, and the patient has
consistently taken risperidone. Thus far, he has not experienced
any skin complications.
Case 2
A 4-year-old boy who was diagnosed with NS was receiving
DFZ (24 mg TID) and enalapril (5 mg QD). After 41 days, he
presented with papules and blisters around the mouth and on
the palms and soles (Fig. 2). He was suspected to have TEN and
was hospitalized.
His vital signs were stable, although he had a fever. The
initial white blood cell count was 14,720 cells/mm3 and the C-
reactive protein level was 1.4 mg/dL. The other laboratory
ﬁndings were normal.
Erythematous papules and blisters rapidly spread on his
body (Z50%) within 3 days. The administration of oral
steroids was discontinued. Ceftriaxone was injected, and IV-
IG (total, 4 g/kg) was administered for 13 days according to the
extent of skin complications. From Day 20 after hospital
admission, the patient showed improvement in the symptoms,
and was subsequently discharged. Thereafter, the medication
was switched to PD, and he has not experienced a relapse
thus far.
Discussion
TEN is a rare but life-threatening disease that involves the
skin and mucosa, and is usually caused by certain drugs [1].The extent of epidermal involvement in TEN is more than 30%
[1,4].
A few recently published cases indicate that TEN might be
induced by steroid use [3,5,6]. In particular, at our center, 40
patients treated with PD did not develop TEN, but three of 54
patients treated with DFZ developed TEN. In Case 1, despite
the initial treatment with PD and DFZ, no skin complications
developed at that time. However, after readministration of
high-dose DFZ for more than 2 weeks, TEN developed. After
remission was achieved, rashes did not reappear even after
switching the treatment to oral PD. PD has also been reported
to potentially cause Stevens–Johnson syndrome (SJS) [7]. TEN
is considered a delayed-type hypersensitivity reaction [1]. The
reaction severity decreases following the discontinuation of
drug administration and develops more rapidly on drug
readministration.
In Case 1, risperidone and atomoxetine were administered
simultaneously. It is unclear whether drug interactions were
involved in the development of TEN. However, these drugs
were administered 6 years previously and the patient did not
present side effects at that time. Consistent with the ﬁndings
in Case 2, Kim et al [3] reported that TEN developed in a
patient with NS treated with DFZ and enalapril. After approxi-
mately 4 weeks of treatment, the condition progressed from
erythematous papules to TEN. Captopril was reported to
possibly cause TEN [8], whereas enalapril may be a causative
agent for TEN when combined with DFZ [3]. Enalapril and
captopril have been suggested to be powerful acantholytic
drugs in vitro, and the active amide group of both drugs could
induce acantholysis [9]. However, Papay et al [10], in their
extensive review of SJS/TEN, have classiﬁed both drugs as
“drugs commonly used but probably not associated with SJS/
TEN.” Kim [5] and Kim et al [6] also reported cases of SJS and
TEN caused by the use of DFZ (Table 1). Their patients did not
receive any other medication, except for DFZ, over 8 weeks.
TEN is considered to be associated with exposure to an agent
during an 8-week period prior to disease onset [1]. To conﬁrm
the relationship between TEN and DFZ, a rechallenge would be
helpful. Kim [5] has suggested that DFZ may be a possible
cause of SJS, based on the results of skin tests and provocation
tests using DFZ. In the present cases, a rechallenge with DFZ
could not be performed due to ethical reasons. The relation-
ship between corticosteroids, especially DFZ, and TEN remains
controversial, and its exact mechanism is not known [11].
Roujeau et al [11] suggested that the risks were particularly
Table 1. Demographics and clinical characteristics of recovered patients
Patient no. Age (y) Sex Underlying disease Causative agent Duration of DFZ Tx. Combined agent Diagnosis Treatment Refs
1 14 M NS, MR DFZ 17 d Risperidone,
atomoxetine
TEN IV-IG Case 1
2 4 M NS DFZ 41 d Enalapril TEN IV-IG Case 2
3 14 M MN stage 3 DFZ 4 wk Enalapril TEN Methylprednisolone,
IV-IG
[3]
4 11 M NS DFZ 8 wk None TEN IV-IG [6]
DFZ, deﬂazacort; IV-IG, intravenous immunoglobulin G; MN, membranous nephropathy; MR, mental retardation; NS, nephrotic syndrome; PD,
prednisolone; TEN, toxic epidermal necrolysis.
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therapy (within 2 months) with most of the commonly
questionable agents, including corticosteroids. An immuno-
suppressive mechanism involving corticosteroids might play a
role in the pathophysiology of SJS/TEN [12]. In numerous cases
of SJS/TEN, the use of multiple medications or co-use of drugs
may cause the development of SJS/TEN [10]. However, most
importantly, the only medication that was common between
the cases and was taken within 8 weeks prior to disease onset
was DFZ. Therefore, we hypothesized that DFZ was more likely
to be the potential cause of TEN, compared with other
medications, although we could not exclude the possible
additional role of enalapril in Case 2.
In most cases, TEN is almost exclusively attributed to drugs;
however, infections by viruses, bacteria, and mycobacteria
could trigger the development of TEN in association with
drugs [1]. Because infection tests, such as herpes simplex virus
tests, other than those for M. pneumonia and human immu-
nodeﬁciency virus, were not performed in the present cases,
we could not clearly exclude the possibility of an infectious
origin. Nevertheless, from the viewpoint of immune suppres-
sion, it should be noted that TEN did not develop in patients
treated with PD.
Several cases have demonstrated an association between
secondary glomerular nephritis such as that in systemic lupus
erythematosus and TEN [13]. In the present cases, renal
biopsies were not performed owing to the parents’ refusal to
undergo this examination; however, no serological abnormal-
ities were noted with regard to the rheumatoid factor, anti-
nuclear antibody, and complement levels.
The pathophysiology of TEN remains controversial [1].
When cytotoxic T lymphocytes come in contact with target
cells, the Fas–Fas ligand pathway is induced and triggers
apoptosis in TEN [14]. Treatment using IV-IG may be a
pathogenetic approach. IV-IG includes autoantibodies against
normal proteins such as Fas. IV-IG likely affects a combination
of many pathways that results in blocking of the interaction of
Fas with FasL [14]. In patients with TEN, an IV-IG dose of 2–4 g/
kg has been recommended for treatment [1,15]. In the present
cases, the patients were administered a total dose of 4.51 g/kg
over 18 days and 4 g/kg over 13 days. The IV-IG was injected at
a dose of 2 g/kg during the ﬁrst 5 days of the onset of skin
eruption, which was reduced depending on the severity of the
skin lesions. The IgG levels were within the normal range. No
adverse effects related to IV-IG therapy, including cephalgia,
low-grade fever, ﬂushing, chills, and myalgia, were noted [15].
The patients needed to be isolated and to be administered
supportive care such as wound management, ﬂuid replace-
ment, respiratory and nutritional support, careful monitoring,and pain management. When TEN develops, patients require
extensive and prolonged treatment and hospitalization.
The reason for the development of TEN in DFZ patients and
not in PD patients is not yet clear. Moreover, the effect of the
combination of medications or infection on the development
of TEN is unclear. Nevertheless, because of the rapid, progres-
sive, and fatal course of TEN associated with DFZ, we believe
that it is essential to perform additional multilateral research
and safety evaluations of DFZ, and that clinicians should be
aware of the serious side effects of this drug when treating
cases of NS.Conﬂict of interest
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